EUVIMEDEUVIMED entdecken
Crossref

Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma

Hisham F Bahmad iD, Kei Shing Oh iD, John Alexis iD

Journal of Cutaneous Pathology · 2023

DOI: 10.1111/cup.14438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2023. Verfasst von Hisham F Bahmad und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Nevus, Pigmented, Nevus. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PRAME (PReferentially expressed Antigen in MElanoma) is a tumor‐associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic neoplasms. Studies on the diagnostic utility of PRAME and p16 in combination in differentiating nevi from melanoma are limited. We aimed to assess the diagnostic utility of PRAME and p16 in melanocytic tumors and their role in distinguishing between malignant melanomas and melanocytic nevi.

Methods

This is a single‐center retrospective cohort analysis over a 4‐year period (2017–2020). We used the pathological database of malignant melanomas (77 cases) and melanocytic nevi (51 cases) specimens from patients who underwent shave/punch biopsies or surgical excisions and evaluated immunohistochemical staining percentage positivity and intensity for PRAME and p16.

Results

Most malignant melanomas showed positive/diffuse PRAME expression (89.6%); on the other hand, 96.1% of nevi did not express PRAME diffusely. p16 was expressed consistently in nevi (98.0%). However, p16 expression in malignant melanoma was infrequent in our study. PRAME had a sensitivity and specificity of 89.6% and 96.1%, respectively, for melanomas versus nevi; on the other hand, p16 had a sensitivity and specificity of 98.0% and 28.6%, respectively, for nevi versus melanoma. Also, a PRAME+/p16− melanocytic lesion is unlikely to be a nevus where most nevi were PRAME−/p16+.

Conclusion

In conclusion, we confirm the potential utility of PRAME and p16 for distinguishing melanocytic nevi from malignant melanomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsNevus, PigmentedNevusNevus, Epithelioid and Spindle CellHumansRetrospective StudiesImmunohistochemistryBiomarkers, TumorAntigens, NeoplasmDiagnosis, DifferentialCutaneous Malignant Melanoma

Stichwörter der Autor:innen

PRAMEdiagnostic biomarkermalignant melanomamelanocytic nevusp16

Substanzen

Biomarkers, TumorAntigens, NeoplasmPRAME protein, human

Autor:innen und Institutionen

  • The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • Department of Pathology, Herbert Wertheim College of Medicine, Florida International University, Miami Beach, Florida, USA.

ORCID-Profile: Hisham F Bahmad, Kei Shing Oh, John Alexis

Zitieren

APA

Bahmad, H. F., Oh, K. S., & Alexis, J. (2023). Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14438

Vancouver

Bahmad HF, Oh KS, Alexis J. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. Journal of Cutaneous Pathology. 2023. doi:10.1111/cup.14438

BibTeX
@article{Bahmad2023,
  author = {Bahmad, Hisham F and Oh, Kei Shing and Alexis, John},
  title = {Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma},
  journal = {Journal of Cutaneous Pathology},
  year = {2023},
  doi = {10.1111/cup.14438}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche